title: [Granulocyte- colony stimulating factor (G-CSF) use in clinical practice in patients receiving chemotherapy for breast cancer: The Opaline Study].
abstract: OBJECTIVE
  To describe the French routine use of G-CSF in patients treated for breast cancer as per the EORTC recommendations.
  
  
  METHODS
  A prospective multicenter observational study conducted between February 2008 and September 2009 in 869 breast cancer patients treated by chemotherapy (CT) and for whom G-CSF treatment will be delivered in primary (PP) or secondary prophylaxis.
  
  
  RESULTS
  The mean age was 55 years. A total of 80.3% of CT was in neoadjuvant/adjuvant setting (NAS). PP was delivered in 78.9% of the NAS patients and 67.5% in metastatic situation. Of the 702 evaluable patients, incidences of severe (SN) and febrile neutropenias (FN) in patients who received PP were 9.3% and 4.2%, respectively. In patients who did not received G-CSF at first cycle, SN and FN were 12.4% and 7.3%, respectively. The use of PP was mainly driven by the type of CT for patients treated in the NAS and by patient or disease related risk factors in the locally advanced/metastatic setting.
  
  
  CONCLUSIONS
  This study has shown that the use of G-CSF was in accordance with the 2010 updates of the EORTC recommendations. However, G-CSF appears more widely used in the routine practice.
authors.affiliation: Institut du cancer de Montpellier (ICM) Val-d'Aurelle, pôle médecine, 34298 Montpellier, France. Electronic address: william.jacot@icm.unicancer.fr.
authors.forename: William
authors.initials: W
authors.lastname: Jacot
authors.affiliation: Clinique Hartmann, service d'oncologie médicale, 92200 Neuilly-sur-Seine, France.
authors.forename: Eric-Charles
authors.initials: EC
authors.lastname: Antoine
authors.affiliation: Hôpital de Chambery, service d'hémato-oncologie, 73000 Chambery, France.
authors.forename: Maya
authors.initials: M
authors.lastname: Hacini
authors.affiliation: CHU de Strasbourg, service d'hémato-oncologie, 67000 Strasbourg, France.
authors.forename: Cathy
authors.initials: C
authors.lastname: Giron
authors.affiliation: Centre François-Baclesse, service d'oncologie médicale, 14000 Caen, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Rivière
authors.affiliation: Institut Paoli-Calmettes, département d'oncologie radiothérapie, 13009 Marseille, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Moureau-Zabotto
authors.affiliation: Centre hospitalier du pays d'Aix, service de gynécologie, 13616 Aix-en-Provence, France.
authors.forename: Daniel
authors.initials: D
authors.lastname: Cassin
authors.affiliation: Institut Jean-Godinot, service d'oncologie médicale, 51100 Reims, France.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Yazbek
authors.affiliation: Centre hospitalier Fleyriat, service d'oncologie médicale, 01012 Bourg-en-Bresse, France.
authors.forename: Hubert
authors.initials: H
authors.lastname: Orfeuvre
authors.affiliation: CHG André-Boulloche, service d'oncologie et de radiothérapie, 25200 Montbelliard, France.
authors.forename: Nacera
authors.initials: N
authors.lastname: Sakek
authors.affiliation: Centre hospitalier Emile-Durkheim, service d'oncologie, 88021 Epinal, France.
authors.forename: Rafik
authors.initials: R
authors.lastname: Diab
authors.affiliation: Clinique Saint-Hilaire, service d'oncologie médicale, 76000 Rouen, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Bastit
authors.affiliation: Médipôle de Savoie, unité oncologie médicale, avenue des Massettes, 73190 Challes-les-Eaux, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Mille
authors.affiliation: Institut du cancer de Montpellier (ICM) Val-d'Aurelle, pôle radiothérapie oncologique, 34298 Montpellier, France.
authors.forename: David
authors.initials: D
authors.lastname: Azria
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D003663:Decision Trees; D005260:Female; D005602:France; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019983:Guideline Adherence; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011322:Primary Prevention; D011446:Prospective Studies; D055502:Secondary Prevention
chemical_list: D016179:Granulocyte Colony-Stimulating Factor
keywords: Chemotherapy; Chimiothérapie; Facteurs de croissance; Febrile neutropenia; Growth factors; Neutropénie fébrile; Prophylaxie; Prophylaxis